Pharmacogenomics in the treatment of narcolepsy
Espana RA, Baldo BA, Kelley AE, Berridge CW.
Pharmacogenomics 2003 Jan;4(1):23-33
Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and cataplexy. Available treatments of narcolepsy include stimulants and antidepressants but the recent discovery of orexin/hypocretin deficiency in narcolepsy opens up new perspectives. Narcolepsy is a complex disorder involving genetic, immune and environmental factors. Although only a strong association is found with the HLA DQB1*0602 gene, other genetic susceptibility factors might be involved. Among these, the functional polymorphism of the catechol-O-methyltransferase (COMT) gene is critically involved in the severity of narcolepsy and in the response to the stimulant modafinil. Other pharmacogenetic targets include the orexinergic, noradrenergic and possibly the serotonergic pathways.
Modafinil and serotonin
Modafinil and the aviator
Modafinil and the marmoset
Modafinil as an antidepressant
Modafinil versus amphetamine
Orexins and forebrain cholinergic neurons